tirzepatide molecule shows 98.7% diabetes prevention at 3 years Tirzepatide: Twincretins as Targeted Therapy

According to data reported in the New England Journal of Medicine [2], higher doses achieved up to 17.5% weight reduction at 24 weeks and over 24% at 48 weeks, alongside consistent HbA1c lowering

In the Phase 2 trial published in the New England Journal of Medicine in 2023, participants on the highest dose of 12mg reported significant reductions in appetite and food intake within the first two weeks

After synthesis, the peptide is purified using high-resolution chromatography, most commonly HPLC , to remove impurities and byproducts

8 Similarly, evidence concerning the association between GLP-1RA medications and pancreatic cancer remains conflicting, with some studies indicating an increased risk while others suggest a potential protective effect